Aerovate Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 12, 2024

JBIO$16.40+5.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)


· · · · · · · · · · · · · · · · ·
· · · · · · · · Accumulated · · · · ·
· · · · · Additional · Other · · · · Total ·
· Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ ·
· Shares · Amount · Capital · Gain/(Loss) · Deficit · Equity ·
Balance at December 31, 2023	27,762,703	$3	$272,640	$237	$(163,424)	$109,456
Unrealized loss on investments	—	—	—	(270)	—	(270)
Issuance of common stock upon exercise of stock options	133,282	—	704	—	—	704
Vesting of restricted stock units	2,776	—	—	—	—	—
Stock based compensation	—	—	4,200	—	—	4,200
Net loss	—	—	—	—	(23,186)	(23,186)
Balance at March 31, 2024	27,898,761	$3	$277,544	$(33)	$(186,610)	$90,904
Unrealized loss on investments	—	—	—	(50)	—	(50)
Issuance of common stock in connection with ATM, net	800,000	—	23,635	—	—	23,635
Issuance of common stock upon exercise of stock options	119,239	—	511	—	—	511
Issuance of common stock under ESPP	34,034	—	308	—	—	308
Vesting of restricted stock units	2,716	—	—	—	—	—
Stock based compensation	—	—	3,865	—	—	3,865
Net loss	—	—	—	—	(24,775)	(24,775)
Balance at June 30, 2024	28,854,750	$3	$305,863	$(83)	$(211,385)	$94,398


· · · · · · · · · · · · · · · · ·
· · · · · · · · · Accumulated · · · ·
· · · · · Additional · · Other · · Total ·
· Common Stock · Paid-In · · Comprehensive · Accumulated · Stockholders’ ·
· Shares · Amount · Capital · Gain/(Loss) · Deficit · Equity ·
Balance at December 31, 2022	24,722,974	$2	$215,110	$(466)	$(87,903)	$126,743
Unrealized gain on investments	—	—	—	265	—	265
Issuance of common stock upon exercise of stock options	93,966	—	223	—	—	223
Stock based compensation	—	—	2,384	—	—	2,384
Net loss	—	—	—	—	(16,520)	(16,520)
Balance at March 31, 2023	24,816,940	$2	$217,717	$(201)	$(104,423)	$113,095
Unrealized loss on investments	—	—	—	(22)	—	(22)
Issuance of common stock in connection with ATM, net	2,662,721	1	44,282	—	—	44,283
Issuance of common stock upon exercise of stock options	106,756	—	333	—	—	333
Issuance of common stock under ESPP	13,866	—	228	—	—	228
Vesting of restricted stock units	815	—		—	—	—
Stock based compensation	—	—	3,034	—	—	3,034
Net loss	—	—	—	—	(19,025)	(19,025)
Balance at June 30, 2023	27,601,098	$3	$265,594	$(223)	$(123,448)	$141,926

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.